XML 45 R31.htm IDEA: XBRL DOCUMENT v3.24.1
INCOME TAXES (Tables)
12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
SCHEDULE OF DOMESTIC AND FOREIGN COMPONENTS

The following table presents domestic and foreign components of consolidated loss before income taxes from continuing operations for the periods presented:

 

  

December 31,

2023

  

December 31,

2022

 
Domestic  $(12,479,803)  $(13,887,914)
Foreign        
Loss before provision for income taxes  $(12,479,803)  $(13,887,914)
SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE

A reconciliation of the statutory income tax rates and the Company’s effective tax rate is as follows:

 

   December 31, 2023   December 31, 2022 
Statutory federal income tax rate   21.00%   21.00%
State taxes, net of federal tax benefit   1.76%   7.50%
Non-deductible expenses   -0.64%   -2.09%
NOL expiration   -5.26%   -19.88%
Tax credit   2.92%   3.71%
Goodwill impairment   0.00%   0.00%
Foreign rate differential   0.00%   0.00%
Change in fair value of warrant liability   3.35%   0.00%
Tax impact of convertible debenture   -5.46%   1.37%
Tax impact of divestiture   -229.26%   4.01%
True-up   -10.65%   2.24%
Change in valuation allowance   222.28%   -17.91%
Income taxes provision (benefit)   0.04%   -0.05%
SCHEDULE OF PROVISION FOR INCOME TAXES

Income tax expense for the year ended December 31, 2023 and 2022 consisted of the following:

 

   December 31, 2023   December 31, 2022 
   For the Years Ended 
   December 31, 2023   December 31, 2022 
Current          
U.S. Federal  $(10,000)  $ 
U.S. State   5,000    7,000 
Total current provision   (5,000)   7,000 
Deferred Benefit          
U.S. Federal   23,128,000    (236,000)
U.S. State   4,697,000    (2,252,000)
Total deferred benefit   27,825,000    (2,488,000)
Change in valuation allowance   (27,825,000)   2,488,000 
Total provision (benefit) for income taxes  $(5,000)  $7,000 
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES

The components of deferred tax assets and liabilities are as follows:

 

   December 31, 2023   December 31, 2022 
Deferred tax assets:          
Net operating loss  $8,644,000   $32,587,000 
Research and development credits   4,970,000    7,857,000 
Accrued expenses   68,000    1,020,000 
Patent        
Stock compensation   3,004,000    3,069,000 
Research and development expenses   1,102,000    1,196,000 
Fixed assets       280,000 
Total deferred income tax assets   17,788,000    46,009,000 
           
Deferred tax liabilities:          
Intangible assets       (13,000)
Right-of-use asset       (382,000)
Total deferred income tax liabilities       (395,000)
           
Net deferred income tax assets   17,788,000    45,614,000 
Valuation allowance   (17,788,000)   (45,614,000)
Deferred tax asset, net of allowance  $   $